50 results on '"Thuerlimann B"'
Search Results
2. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
3. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
4. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
5. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
6. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99
7. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
8. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
9. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
10. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
11. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
12. Predictors of state-of-the-art management of early breast cancer in Switzerland
13. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
14. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
15. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
16. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
17. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
18. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study
19. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
20. First—select the target: better choice of adjuvant treatments for breast cancer patients
21. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
22. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
23. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
24. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
25. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
26. Bevacizumab-associated osteonecrosis of the jaw
27. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
28. Capecitabine and vinorelbine in elderly patients (≥65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
29. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
30. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
31. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
32. A randomized double-blind trial to compare the clinical efficacyof granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis
33. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
34. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study
35. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma
36. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
37. Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial)
38. Corrections to “De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017”
39. 288PD - PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)
40. Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
41. Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al.
42. 1389PD - Prognostic impact of drug interactions in patients with advanced cancer
43. 300P - Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial)
44. 1552TiP - Prevention of Symptomatic Skeletal Events with Denosumab Administered Every 4 Weeks Versus Every 12 Weeks–A Non-Inferiority Phase III Trial: Sakk 96/12 - Reduse
45. 301P - Predictors of Hypertension in Ibcsg 18-98 / Big 1-98: Adjuvant Therapy for Postmenopausal Women with Hormone Receptor-Positive, Early Breast Cancer
46. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI
47. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
48. Original article: Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: A prospective randomized crossover trial
49. Effective prevention of chemotherapy—induced phlebitis by low-dose heparin: A prospective randomised trial
50. Book review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.